In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Mesoblast (MESO – Research Report), with a price target of $10.00. The company’s shares closed last Tuesday at $2.48, close to its 52-week low of $2.32.
According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -42.0% and a 9.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.
Mesoblast has an analyst consensus of Moderate Buy, with a price target consensus of $10.13.
Mesoblast’s market cap is currently $304.1M and has a P/E ratio of -3.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
Read More on MESO: